Biodistribution and pharmacokinetics in rats and antitumor effect in various types of tumor-bearing mice of novel self-assembled gelatin-oleic acid nanoparticles containing paclitaxel

Journal of Biomedical Nanotechnology

Volumn 10, Issue 1, 2014, Pages 154-165

  Tran, Phuong Ha Lien ^a   Tran, Thao Truong Dinh ^a   Lee, Beom Jin ^b  

^a INTERNATIONAL UNIVERSITY   (Viet Nam)

^b Ajou University   (South Korea)

Author keywords

Biodistribution; Gelatin oleic acid conjugate; In vivo antitumor efficacy; Pharmacokinetics; Self assembled nanoparticles; Tumor bearing mice

Indexed keywords

ANTI-TUMOR EFFICACY; BIODISTRIBUTIONS; GELATIN-OLEIC ACID CONJUGATE; SELF ASSEMBLED NANOPARTICLES; TUMOR-BEARING MICE;

BIOCOMPATIBILITY; CARDIOVASCULAR SYSTEM; DRUG DELIVERY; DRUG DOSAGE; LIGANDS; NANOPARTICLES; OLEIC ACID; PHARMACOKINETICS; RATS; TUMORS;

SYNTHESIS (CHEMICAL);

DRUG CARRIER; FOLIC ACID; GELATIN OLEIC ACID NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TISSUE LEVEL; FEMALE; IN VIVO STUDY; LD 50; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; FEMALE; GELATIN; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS; OLEIC ACID; PACLITAXEL; POLYMERIZATION; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 84889059742     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1660     Document Type: Article

References (50)

1. R. O'Neill, FDA's critical path initiative: A perspective on contributions of biostatistics. Biom. J. 48, 559 (2006).
2. A. Sailaja, P. Amareshwar, and P. Chakravarty, Chitosan nanoparticles as a drug delivery system. Res. J. Pharm. Bio. Chem. Sci. 1, 474 (2010).
3. S.-D. Li and L. Huang, Pharmacokinetics and Biodistribution of Nanoparticles. Mol. Pharm. 5, 496 (2008).
4. P. H.-L. Tran, T. T.-D. Tran, T. V. Vo, C. L.-N. Vo, and B.-J. Lee, Novel multifunctional biocompatible gelatin-oleic acid conjugate: Self-assembled nanoparticles for drug delivery. J. Biomed. Nanotechnol. 9, 1416 (2013).
5. S. Azarmi, Y. Huang, H. Chen, S. McQuarrie, D. Abrams, W. Roa, W. Finlay, G. Miller, and R. Lobenberg, Optimization of a twostep desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J. Pharm. Pharm. Sci. 9, 124 (2006).
6. 1-receptor antagonist. Chem. Pharm. Bull. 50, 87 (2002).
7. A. Ledo-Suarez, L. Rodriguez-Sanchez, M. Blanco, and M. Lopez-Quintela, Electrochemical synthesis and stabilization of cobalt nanoparticles. Phys. Stat. Sol. 203, 1234 (2006).
8. W. Franklin, M. Waintrub, D. Edwards, K. Christensen, P. Prendegrast, J. Woods, P. Bunn, and J. Kolhouse, New anti-lung cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int. J. Cancer. Suppl. 8, 89 (1994).
9. S. Weitman, R. Lark, L. Coney, D. Fort, V. Frasca, V. J. Zurawski, and K. BA, Distribution of the folate receptor GP38 in normal and malignat cell lines and tissues. Cancer Res. 52, 3396 (1992).
10. L. Vlerken and M. Amiji, Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin. Drug Deliv. 3, 205 (2006).
11. E. Bilensoy, O. Gurkaynak, A. L. Dodan, and A. A. Hincal, Safety and efficacy of amphiphilic s-cyclodextrin nanoparticles for paclitaxel delivery. Int. J. Pharm. 347, 163 (2008).
12. C. M. Spencer and D. Faulds, Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48, 794 (1994).
13. E. Rowinsky, Clinical pharmacology of taxol. Monogr. Natl. Cancer Inst. 15, 25 (1993).
14. R. B. Weiss, R. C. Donehower, and P. H. Wiernik, Hypersensitivity reactions from taxol. J. Clin. Oncol. 8, 1263 (1990).
15. W. Waugh, L. A. Trissel, and V. J. Stella, Stability, compatibility and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am. J. Hosp. Pharm. 48, 1520 (1997).
16. A. K. Singla, A. Garg, and D. Aggarwal, Paclitaxel and its formulations. Int. J. Pharm. 235, 179 (2002).
17. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom, Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. European journal of cancer (Oxford, England: 1990), 37, 1590 (2001).
18. I. Brigger, C. Dubernet, and P. Couvreur, Nanoparticles in cancer therapy and diagnosis. Adv. Drug Delivery Rev. 64, 24 (2012).
19. V. S. Shenoy, R. P. Gude, and R. S. Ramchandra Murthy, Paclitaxel-loaded glyceryl palmitostearate nanoparticles: In vitro release and cytotoxic activity. J. Drug Target 17, 304 (2009).
20. A. L. Z. Lee, Y. Wang, H. Y. Cheng, S. Pervaiz, and Y. Y. Yang, The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30, 919 (2009).
21. J. You, XinLi, FudeCui, Y.-Z. Du, HongYuan, and F. q. Hu, Folate-conjugated polymer micelles factive targeting to cancer cells: Preparation, in vitro evaluation of targeting ability and cytotoxicity. Nanotechnology 19, 045102 (2008).
22. Y. Patil, T. Sadhukha, L. Ma, and J. Panyam, Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control Release 136, 21 (2009).
23. S. J. Lee, G.-Y. Hong, Y.-I. Jeong, M.-S. Kang, J.-S. Oh, C.-E. Song, and H. C. Lee, Paclitaxel-incorporated nanoparticles of hydrophobized polysaccharide and their antitumor activity. Int. J. Pharm. 433, 121 (2012).
24. J. Xu, L. Ma, Y. Liu, F. Xu, J. Nie, and G. Ma, Design and characterization of antitumor drug paclitaxel-loaded chitosan nanoparticles by W/O emulsions. Int. J. Biol. Macromol. 50, 438 (2012).
25. L. Li, J. K. Kim, K. M. Huh, Y.-k. Lee, and S. Y. Kim, Targeted delivery of paclitaxel using folate-conjugated heparin-poly (β-benzyl-l-aspartate) self-assembled nanoparticles. Carbohydr. Polym. 87, 2120 (2012).
26. G. D. Venkatasubbu, S. Ramasamy, G. S. Avadhani, V. Ramakrishnan, and J. Kumar, Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles. Powder Technol. 235, 437 (2013).
27. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505 (2008).
28. Y. B. Patil, U. S. Toti, A. Khdair, L. Ma, and J. Panyam, Singlestep surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials 30, 859 (2009).
29. R. Steel and J. Torrie, Principles and Procedures of Statistics, A Biometrical Approach, 2nd ed., McGraw-Hill, New York (1980).
30. Guidance for industry: Bioanalytical method validation, in, U. S. Department of Health and Human Services, Food and Drug Administration. Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM) (2001).
31. C. Zhang, G. W. Qu, Y. J. Sun, X. J. Wu, Z. L. Yao, Q. L. Guo, Q. O. Ding, S. T. Yuan, Z. L. Shen, Q. E. Ping, and H. P. Zhou, Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 29, 1233 (2008).
32. N. Shah, K. Chaudhari, P. Dantuluri, R. S. Murthy, and S. Das, Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic ((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model. J. Drug Target 17, 533 (2009).
33. Y.-Y. Yang, Y. Wang, R. Powell, and P. Chan, Polymeric core- shell nanoparticles for therapeutics. Clin. Exp. Pharmacol. Physiol. 33, 557 (2006).
34. S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain, Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 95, 4607 (1998).
35. H. Maeda, The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul 41, 189 (2001).
36. R. Eisenstein, Angiogenesis in arteries: review. Pharmacol. Ther. 49, 1 (1991).
37. K. Greish, Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J. Drug Target 15, 457 (2007).
38. J. Folkman, What is the role of endothelial cells in angiogenesis. Lab Invest. 51, 601 (1984).
39. J. Folkman, Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182 (1971).
40. E. Rowinsky and R. Donehower, The clinical pharmacology of paclitaxel (Taxol). Semin. Oncol. 20, 16 (1993).
41. T. K. Yeh, Z. Lu, M. G. Wientjes, and J. L. S. Au, Formulating paclitaxel in nanoparticles alters its disposition. Pharm. Res. 22, 867 (2005).
42. Z. H. Xu, W. W. Gu, J. Huang, H. Sui, Z. H. Zhou, Y. X. Yang, Z. Yan, and Y. P. Li, In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int. J. Pharm. 288, 361 (2005).
43. S. C. Kim, D. W. Kim, Y. H. Shim, J. S. Bang, H. S. Oh, S. W. Kim, and M. H. Seo, In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J. Control Release 72, 191 (2001).
44. J. H. Kim, Y. S. Kim, S. Kim, J. H. Park, K. Kim, K. Choi, H. Chung, S. Y. Jeong, R. W. Park, I. S. Kim, and I. C. Kwon, Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel (Reprinted from Journal of Controlled Release, vol 109, p. 1 (2005), J. Control Release 111, 228 (2006).
45. M. K. Jang, Y. I. Jeong, and J. W. Nah, Characterization and preparation of core-shell type nanoparticle for encapsulation of anticancer drug. Colloids and Surfaces B-Biointerfaces 81, 530 (2010).
46. M. M. Janat-Amsbury, J. W. Yockman, M. Lee, S. Kern, D. Y. Furgeson, M. Bikram, and S. W. Kim, Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol. Ther. 9, 829 (2004).
47. X. R. Li, Z. L. Yang, K. W. Yang, Y. X. Zhou, X. W. Chen, Y. H. Zhang, F. Wang, Y. Liu, and L. J. Ren, Self-assembled polymeric micellar nanoparticles as nanocarriers for poorly soluble anticancer drug ethaselen. Nanoscale Research Letters 4, 1502 (2009).
48. A. Freeman and E. Mayhew, Targeted drug delivery. Cancer 58, 573 (1986).
49. D. F. Emerich and C. G. Thanos, Targeted nanoparticle-based drug delivery and diagnosis. J. Drug Target 15, 163 (2007).
50. E. S. Lee, K. Na, and Y. H. Bae, Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 5, 325 (2005).